Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Lichten

Physical Medicine & Rehabilitation Reading, PA Medical Doctor

NPI 1366563744 CMS profile 197580

1623 Morgantown Road, Suite A, Reading, PA 19607

Open in the dashboard

General payments

$117,080

340 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Lichten of Reading, PA is reported in the CMS Open Payments database as having received $117,080 across 340 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $273 10
2024 General $465 23
2023 General $1,342 51
2022 General $616 32
2021 General $270 14
2020 General $28,888 69
2019 General $85,225 141

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Lichten
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to David Lichten were reported at $273. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year David Lichten Physical Medicine & Rehabilitation median Middle half National median
2019 $85,225 $133 $45–$390 $163
2020 $28,888 $88 $29–$272 $114
2021 $270 $116 $33–$360 $132
2022 $616 $123 $40–$378 $149
2023 $1,342 $131 $43–$396 $160
2024 $465 $141 $45–$409 $164
2025 $273 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. US WorldMeds, LLC $88,395 144 payments
  2. Flexion Therapeutics, Inc. $20,631 26 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $4,120 10 payments
  4. Collegium Pharmaceutical, Inc. $571 26 payments
  5. Amgen Inc. $448 20 payments
  6. Scilex Pharmaceuticals Inc. $439 20 payments
  7. Abbott Laboratories $430 17 payments
  8. Boston Scientific Corporation $332 13 payments
  9. Vertos Medical, Inc. $286 2 payments
  10. Nevro Corp. $163 3 payments
  11. Other $1,264 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $76,500 34 payments
  2. Honoraria $20,650 12 payments
  3. Travel and Lodging $6,034 52 payments
  4. Food and Beverage $5,966 240 payments
  5. Consulting Fee $4,930 1 payment
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,000 1 payment
Products named General payments · program years 2019–2025
  1. Lucemyra/Lofexidine $87,752 136 payments
  2. Zilretta $20,631 26 payments
  3. RELISTOR $4,120 10 payments
  4. EVENITY $448 20 payments
  5. ZTLido $416 19 payments
  6. XTAMPZA $397 17 payments
  7. Prolia $283 18 payments
  8. mild Device Kit $189 1 payment
  9. PROCLAIM $184 5 payments
  10. WaveWriter Alpha Prime 16 $181 5 payments
  11. Other $2,246 100 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

525

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$12,826

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

6.9%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Er Gabapentin Brand 11 $8,431
Gabapentin Generic 139 $1,245
Pregabalin Generic 19 $561
Duloxetine Hcl Generic 11 $537
Tramadol Hcl Er Tramadol Hcl Brand 13 $522
Tramadol Hcl Generic 57 $302
Meloxicam Generic 90 $252
Prednisone Generic 55 $223
Morphine Sulfate Er Morphine Sulfate Brand 12 $208
Oxycodone Hcl Generic 15 $152

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$292,122

Of which drugs: $55,162

Medicare patients

335

Average age 73

Services billed

8,014

221 women, 114 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 35%
Diabetes 30%
Depression 30%
Chronic kidney disease 27%
Ischemic heart disease 26%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 41 2,580 $54,827
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 145 3,161 $284
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 128 236 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZTLido
  • Scilex Pharmaceuticals Inc. $115
$115 — —
XTAMPZA
  • Collegium Pharmaceutical, Inc. $89
$89 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $58
$58 — —
EVENITY
  • Amgen Inc. $26
$26 — —
Prolia
  • Amgen Inc. $26
$26 — 2,580

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

340 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record